Next-Generation Sequencing (NGS) for the Study of the Mechanism of Crizotinib Resistance in Patients with ROS1 Positive Non-Small Cell Lung Cancer (NSCLC).
Latest Information Update: 31 Jul 2020
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Jul 2022 form has been assumed from RDI while info. about the route has been given in inclusion criteria, seems there is a typo error in clotriminib .
- 31 Jul 2020 New trial record